Barclays today cut its credit rating on Pfizer (US7170811035) from "Overweight" to "Equal-weight" and the price target at $19. According to the investment bank, the stock of the world leader in the pharmaceutical industry has only limited potential in the short term. Barclays also indicates that Pfizer will face a long-term decline in its core business due to the expiration of the patent coverage of its main products.
Wednesday, September 14, 2011 – 
